Insider Selling: Moderna (NASDAQ:MRNA) Director Sells $264,951.66 in Stock

Moderna, Inc. (NASDAQ:MRNA) Director Abbas Hussain sold 5,682 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $46.63, for a total value of $264,951.66. Following the transaction, the director owned 12,066 shares of the company’s stock, valued at approximately $562,637.58. This trade represents a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Moderna Trading Up 4.5%

MRNA opened at $48.79 on Thursday. The stock has a market capitalization of $19.36 billion, a PE ratio of -5.99 and a beta of 1.05. The firm’s fifty day moving average price is $51.74 and its 200 day moving average price is $39.76. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $59.55.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The company had revenue of $389.00 million for the quarter, compared to the consensus estimate of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The company’s revenue was up 260.2% compared to the same quarter last year. During the same quarter last year, the company earned ($2.52) earnings per share. As a group, research analysts expect that Moderna, Inc. will post -7.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Moderna

Several institutional investors have recently modified their holdings of the company. Assetmark Inc. boosted its position in shares of Moderna by 35.1% during the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after buying an additional 208 shares during the period. New Mexico Educational Retirement Board raised its position in shares of Moderna by 1.9% during the 4th quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock worth $463,000 after buying an additional 300 shares in the last quarter. Cromwell Holdings LLC raised its position in shares of Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after buying an additional 341 shares in the last quarter. IFP Advisors Inc lifted its stake in shares of Moderna by 5.4% in the 4th quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock worth $200,000 after acquiring an additional 348 shares during the period. Finally, Empowered Funds LLC boosted its holdings in shares of Moderna by 2.6% in the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock valued at $405,000 after acquiring an additional 353 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Peer?reviewed Phase 3 data show Moderna’s mRNA?1010 flu vaccine outperformed a standard licensed flu shot in adults 50+, and the results were published in the New England Journal of Medicine; regulatory filings are under review in the U.S., EU, Canada and Australia with potential approvals beginning in 2026 — a material commercial opportunity beyond COVID vaccines. Moderna Announces NEJM Publication of Phase 3 mRNA-1010 Data
• Positive Sentiment: Analyst upgrade: Piper Sandler initiated/issued a Buy on MRNA, which can add upward pressure on the stock by improving investor sentiment and flow into the shares. Piper Sandler Buy Rating
• Neutral Sentiment: Insider activity: Director Abbas Hussain sold ~5,682 shares under a pre?arranged 10b5?1 plan; such planned sales are often neutral but can be read by some investors as signal to monitor. Director Share Sale Filing
• Negative Sentiment: Partner setback: Vertex dropped the Moderna?partnered inhaled cystic fibrosis candidate after unresolved tolerability issues — a tangible pipeline disappointment that narrows near?term optionality and could weigh on sentiment. Vertex Drops Inhaled CF Candidate
• Negative Sentiment: Analyst estimate revisions: Brookline Capital Markets adjusted several quarterly and FY forecasts (mix of downgrades and tweaks), reflecting ongoing uncertainty around near?term profitability and modeling for revenue cadence — a reminder earnings remain negative and volatile. Analyst Estimate Revisions

Wall Street Analyst Weigh In

A number of equities analysts recently commented on MRNA shares. Leerink Partners reiterated an “underperform” rating on shares of Moderna in a research note on Friday, January 30th. Wall Street Zen raised Moderna from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. The Goldman Sachs Group lifted their target price on Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. TD Cowen reissued a “hold” rating on shares of Moderna in a research report on Thursday, January 29th. Finally, Citigroup restated a “neutral” rating on shares of Moderna in a research note on Monday, February 16th. Two equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have issued a Sell rating to the stock. According to data from MarketBeat.com, Moderna has an average rating of “Reduce” and a consensus price target of $35.73.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.